View in EDS

A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance.

Saved in:
Bibliographic Details
Title: A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance.
Authors: Yap TA; University of Texas MD Anderson Cancer Center, Houston, Texas., LoRusso PM; Yale Cancer Center, New Haven, Connecticut., Wong DJ; UCLA Jonsson Comprehensive Cancer Center, Los Angeles California., Hu-Lieskovan S; UCLA Jonsson Comprehensive Cancer Center, Los Angeles California., Papadopoulos KP; South Texas Research Accelerated Therapeutics (START), San Antonio, Texas., Holz JB; F-star Therapeutics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Grabowska U; F-star Therapeutics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Gradinaru C; F-star Therapeutics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Leung KM; F-star Therapeutics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Marshall S; F-star Therapeutics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Reader CS; F-star Therapeutics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Russell R; F-star Therapeutics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Sainson RCA; F-star Therapeutics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Seal CJ; F-star Therapeutics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Shepherd CJ; F-star Therapeutics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Germaschewski F; F-star Therapeutics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Gliddon D; F-star Therapeutics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Stern O; F-star Therapeutics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Young L; F-star Therapeutics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Brewis N; F-star Therapeutics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Kayitalire L; F-star Therapeutics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Morrow M; F-star Therapeutics Ltd., Babraham Research Campus, Cambridge, United Kingdom.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Mar 01; Vol. 29 (5), pp. 888-898.
Publication Type: Research Support, Non-U.S. Gov't; Journal Article
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-22-1449